Please wait while we load the requested 10-K report or click the link below:
March 13, 2018
Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
LEXINGTON, MA Pulmatrix, Inc. (NASDAQ: PULM) today announces 2017 financial results, reviews the Companys recent progress, and provides an outlook for its pulmonary disease development pipeline.
The Company continues to advance its iSPERSE-based product candidates, said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. We expect Phase 1b data in mid-2018 on Pulmazole targeting fungal infections for severe asthma and cystic fibrosis patients. We also expect non-clinical safety data on PUR1800 in the second half of 2018.
Projected 2018 Milestones
|||Single dose escalation phase of the first-in-human study for Pulmazole commenced in February 2018.|
|||Phase 1/1b study results expected mid-2018.|
|||Phase 2a study expected to begin in Q4-2018.|
|||Complete CMC development work and 28-day GLP inhalation toxicology studies in preparation for Phase 2a anti-inflammatory efficacy study in 2019.|
|||Pulmatrix expects that pre-agreed pharmaceutical development criteria will be achieved, which will trigger a technology access fee of $1 million payable by Vectura to Pulmatrix in the second half of 2018.|
2018 YTD and 2017 Progress
Pulmatrix achieved several research, clinical and business milestones which reflect the Companys progress. These milestones include the following:
|||Dosed first patient in Phase 1b clinical study of Pulmazole.|
|||Received authorization of its Clinical Trial Application from the UK Medicines and Healthcare Products Regulatory Agency to initiate its first-in-human study for Pulmazole.|
|||Received a second QIDP status for Pulmazole to treat fungal infections in the airways of allergic bronchopulmonary aspergillosis patients.|
|||Received award from Cystic Fibrosis Foundation Therapeutics to support the development of its lead inhaled anti-fungal product candidate Pulmazole.|
|||Partnered with Vectura Group plc to develop Pulmatrixs drug candidate, PUR0200, for chronic obstructive pulmonary disease for the U.S. market.|
|||Received qualified infectious disease product (QIDP) status for Pulmazole inhaled antifungal to treat fungal infections in the airways of cystic fibrosis patients.|
|||Completed an agreement to in-license narrow spectrum kinase inhibitors from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.|
Pulmatrix ended 2017 with $3.6 million in cash and cash equivalents compared to $6.4 million as of September 30, 2017.
Revenue for 2017 was $0.3 million, compared to $0.8 million for 2016. The decrease was the result of the conclusion of the clinical study funded under our collaboration agreement with Mylan in 2016, partially offset by the revenue from the CFFT award in 2017.
The following information was filed by Pulmatrix, Inc. (PULM) on Tuesday, March 13, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Pulmatrix, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Pulmatrix, Inc..